Get the Stockscreener App
82.62
6.47%
-5.72
Celcuity Inc stock is traded at $82.62, with a volume of 1.29M.
It is down -6.47% in the last 24 hours and down -14.28% over the past month.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
See More
Previous Close:
$88.34
Open:
$89.56
24h Volume:
1.29M
Relative Volume:
0.83
Market Cap:
$4.03B
Revenue:
-
Net Income/Loss:
$-192.89M
P/E Ratio:
-21.20
EPS:
-3.8976
Net Cash Flow:
$-172.97M
1W Performance:
-6.52%
1M Performance:
-14.28%
6M Performance:
-24.93%
1Y Performance:
+488.04%
1-Day Range:
$82.23
$89.56
1-Week Range:
$82.23
$92.66
52-Week Range:
$13.59
$151.02
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
82.62 | 4.03B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity Inc. (CELC) Investor Outlook: Analyzing an 85% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Celcuity's Revtorpyk approval fuels blockbuster expectations - S&P Global
CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug - Stocktwits
Price to sales forward of Celcuity Inc. – NASDAQ:CELC - TradingView
Celcuity faces securities fraud probe after FDA delays breast cancer drug launch, shares drop 17.6%. - Pluang
Bronstein, Gewirtz & Grossman, LLC Is Investigating Celcuity Inc. (CELC) And Encourages Stockholders to Connect - ACCESS Newswire
With FDA approval, Celcuity sees big future for its new breast cancer drug - Star Tribune
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
Celcuity Inc. (CELC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win - Yahoo Finance
CELC stock clocks best day in about 2 months on first FDA approval for cancer drug - MSN
Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer - Sahm
Celcuity falls as rollout concerns overshadow FDA approval of breast cancer drug - MSN
Kirby McInerney LLP investigates Celcuity for p... - Pluang
CELC INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Investors to Inquire about Securities Investigation - Stockhouse
Celcuity (CELC) Stock May Be Overvalued After REVTORPYK Approval - webull.com
Celcuity (CELC) Receives a Buy from Leerink Partners - The Globe and Mail
Precision Trading with Celcuity Inc. (CELC) Risk Zones - Stock Traders Daily
Celcuity got its cancer drug approved. Then its stock dipped - Endpoints News
Form 4 Celcuity LLC For: 16 July By Investing.com - Investing.com Nigeria
Form 13D/A Celcuity Inc. For: 16 July By Investing.com - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc.CELC - PR Newswire
Baker Bros. Advisors LP sells $317.75m Celcuity shares at $102.50 - Investing.com Nigeria
Baker Bros. Advisors LP sells $317.75m Celcuity shares at $102.50 By Investing.com - Investing.com South Africa
Form 13D/A Celcuity Inc. For: 16 July - Investing.com India
Craig-Hallum Sticks to Their Buy Rating for Celcuity (CELC) - The Globe and Mail
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $155 to $178 - Moomoo
Celcuity's REVTORPYK Approval: A Multi-Billion Dollar Breakthrough Despite High Expectations - Kavout | AI
Celcuity (CELC) Experiences Significant Decline - GuruFocus
Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer - MedCity News
Celcuity shares fall as launch delay eclipses US approval for breast cancer drug - Classic Rock 103.5 WIMZ
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits - Investor's Business Daily
US FDA approves Celcuity's breast cancer drug - MSN
Stifel reiterates Celcuity stock rating on FDA approval of Revtorpyk By Investing.com - Investing.com South Africa
Celcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026 (CELC) - Seeking Alpha
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval - MSN
Celcuity gains FDA approval for closely watched breast cancer drug - BioPharma Dive
Celcuity’s Revtorpyk wins FDA nod in breast cancer - BioWorld News
Celcuity’s breast cancer drug approved, its first - STAT
Needham Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $157 - Moomoo
Celcuity Slides as Investors Appear to Take Profits After FDA Approval - Moomoo
Celcuity (CELC) Sees a 12.6% Decline in Stock Price - GuruFocus
Citizens raises Celcuity stock price target to $177 on drug approval - Investing.com UK
Celcuity falls despite FDA nod for breast cancer drug (CELC) - Seeking Alpha
Correction to Celcuity Gets FDA Approval Headline - Moomoo
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):